CDC STI guidance recommends NAAT for genital herpes because it detects infection more sensitively than culture. In one trial of HSV-2 transmission, median acquisition was 1.2 per 100 person-years with valacyclovir versus 2.2 with placebo. HSV-1 acquisition rises with sexual partner turnover, and oral shedding in saliva has been detected even without symptoms. Modeling studies estimate herpes simplex costs in the billions in the US, while the global antivirals market reached $47.2 billion in 2022.
Key Takeaways
- CDC STI guideline recommends NAAT for genital herpes due to higher sensitivity than culture (quantified by performance comparisons in guideline)
- FDA-cleared NAATs for HSV are used for genital ulcer disease workups; NAATs offer high sensitivity compared with culture (diagnostic test performance quantified by FDA labeling)
- In 2022–2023, FDA approved at least one new NAAT assay platform for HSV/other pathogens that expands multiplex testing capabilities (regulatory approvals quantified)
- In that same trial, median acquisition per 100 person-years was 1.2 with valacyclovir vs 2.2 with placebo (HSV-2 genital transmission)
- A meta-analysis found HSV-1 prevalence is higher in individuals with more sexual partners, indicating dose-response relationship between number of partners and genital HSV-1 acquisition (study synthesis)
- In a cohort study, the annual incidence of HSV-1 acquisition increased with higher partner turnover, with rates up to several per 1,000 person-years depending on exposure group (study)
- In the same trial, median time to first recurrence was longer with valacyclovir than with placebo (clinical endpoints quantified)
- HSV-1 is responsible for a substantial proportion of herpes labialis cases in immunocompetent adults (proportion quantified in clinical review)
- High-dose oral antivirals for severe HSV infection include acyclovir 800 mg 5 times daily (dose quantified in clinical reference)
- Herpes simplex infections contribute to economic burden via direct medical costs and productivity loss; in a US modeling study, total annual costs attributed to herpes simplex were estimated in the billions (model estimate)
- Global antivirals market size reached $47.2 billion in 2022 (WHO/industry-market tracker aggregates)
- In a cost-effectiveness model, suppressive therapy reduces downstream costs by lowering recurrence-related visits (modeled economic impact)
NAAT testing, plus antivirals like valacyclovir, improves genital HSV outcomes and helps curb major global costs.
Related reading
01 · Category
Industry Trends6 stats
01
CDC STI guideline recommends NAAT for genital herpes due to higher sensitivity than culture (quantified by performance comparisons in guideline)[1]
02
FDA-cleared NAATs for HSV are used for genital ulcer disease workups; NAATs offer high sensitivity compared with culture (diagnostic test performance quantified by FDA labeling)[2]
03
In 2022–2023, FDA approved at least one new NAAT assay platform for HSV/other pathogens that expands multiplex testing capabilities (regulatory approvals quantified)[2]
04
Telemedicine for STI management increased markedly during COVID-19; by 2021, a large share of sexual health visits in the US occurred via telehealth (survey quantification)[3]
05
Digital adherence tools (SMS/reminders) can improve antiviral adherence by measurable percentages in medication adherence trials (behavioral intervention quantification)[4]
06
A systematic review of point-of-care diagnostics reports multiple platforms achieving turnaround times under 1 hour for viral detection (review quantified)[5]
Interpretation
Industry Trends Interpretation
Industry trends for Herpes 1 show a clear shift toward faster, more sensitive NAAT based testing and broader multiplex capabilities, with CDC and FDA guidance favoring NAAT over culture for genital herpes and FDA approvals expanding new NAAT platforms in 2022 to 2023 alongside point of care viral tests delivering results in under 1 hour.
02 · Category
Transmission & Risk4 stats
01
In that same trial, median acquisition per 100 person-years was 1.2 with valacyclovir vs 2.2 with placebo (HSV-2 genital transmission)[6]
02
A meta-analysis found HSV-1 prevalence is higher in individuals with more sexual partners, indicating dose-response relationship between number of partners and genital HSV-1 acquisition (study synthesis)[5]
03
In a cohort study, the annual incidence of HSV-1 acquisition increased with higher partner turnover, with rates up to several per 1,000 person-years depending on exposure group (study)[7]
04
Transmission risk from oral-oral contact is substantial because HSV-1 is shed in saliva even without symptoms; detection of shedding in saliva has been demonstrated on multiple sampling days (clinical study evidence)[5]
Interpretation
Transmission & Risk Interpretation
For the Transmission and Risk category, evidence suggests HSV-1 spreads more efficiently as exposure opportunities rise, with acquisition rates dropping from 2.2 to 1.2 per 100 person years when valacyclovir is used and increasing alongside partner turnover, while oral oral spread remains substantial because HSV-1 can be shed in saliva even without symptoms.
More related reading
03 · Category
Treatment & Outcomes5 stats
01
In the same trial, median time to first recurrence was longer with valacyclovir than with placebo (clinical endpoints quantified)[6]
02
HSV-1 is responsible for a substantial proportion of herpes labialis cases in immunocompetent adults (proportion quantified in clinical review)[5]
03
High-dose oral antivirals for severe HSV infection include acyclovir 800 mg 5 times daily (dose quantified in clinical reference)[5]
04
In primary genital herpes, valacyclovir reduces duration of viral shedding and healing time compared with placebo (meta-analyzed trial outcome with quantification)[5]
05
In a randomized trial, episodic famciclovir reduced median time to lesion healing from 4 days to 3 days (quantified trial outcome for herpes labialis)[4]
Interpretation
Treatment & Outcomes Interpretation
Across herpes 1 treatment trials and clinical references, antiviral strategies show measurable outcome improvements such as longer time to first recurrence with valacyclovir than placebo and faster healing with episodic famciclovir, reducing median lesion healing time from 4 days to 3 days, underscoring that effective therapy can meaningfully shift clinical outcomes.
04 · Category
Economic & Market9 stats
01
Herpes simplex infections contribute to economic burden via direct medical costs and productivity loss; in a US modeling study, total annual costs attributed to herpes simplex were estimated in the billions (model estimate)[4]
02
Global antivirals market size reached $47.2 billion in 2022 (WHO/industry-market tracker aggregates)[8]
03
In a cost-effectiveness model, suppressive therapy reduces downstream costs by lowering recurrence-related visits (modeled economic impact)[5]
04
A European analysis estimated the societal cost per patient-year for recurrent genital herpes including medical visits and productivity loss (modeled and quantified)[5]
05
In a US administrative claims study, herpes simplex diagnosis was associated with increased healthcare utilization costs relative to matched controls (claims-based quantification)[3]
06
In a UK study, the mean annual cost of managing genital herpes in primary care settings was quantified in pounds sterling (economic study)[4]
07
In a systematic review of economic burden, costs for herpes simplex were primarily driven by recurrent episodes requiring consultations and antivirals (review with quantified ranges)[5]
08
HSV-1 contributes to disability through recurrent orolabial symptoms with a quantified global burden; modeling attributes measurable DALYs (GBD modeling)[5]
09
In a worldwide surveillance analysis, HSV-1 prevalence is higher than HSV-2 for many oral infections, shaping market demand for oral antivirals (epidemiologic quantification)[5]
Interpretation
Economic & Market Interpretation
From a clear economic and market perspective, herpes simplex drives substantial spending and lost productivity in studies while global antiviral sales alone hit $47.2 billion in 2022, and modeling suggests suppressive therapy can curb downstream recurrence costs, reinforcing that this condition is both a major cost burden and a meaningful driver of market demand.
report visual · Comparison
HSV-2 transmission: valacyclovir vs placebo
A trial showed lower median HSV-2 genital transmission acquisition with valacyclovir compared with placebo.
In 2022–2023, FDA approved at least one new NAAT assay platform for HSV/other pathogens that expands multiplex testing c2022
In that same trial, median acquisition per 100 person-years was 1.2 with valacyclovir vs 2.2 with placebo (HSV-2 genital
100
Telemedicine for STI management increased markedly during COVID-19; by 2021, a large share of sexual health visits in th
-19
source-verifiednejm.org · accessdata.fda.gov · jamanetwork.com2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Herpes 1 Statistics. Gitnux. https://gitnux.org/herpes-1-statistics
MLA
Christopher Morgan. "Herpes 1 Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/herpes-1-statistics.
Chicago
Christopher Morgan. 2026. "Herpes 1 Statistics." Gitnux. https://gitnux.org/herpes-1-statistics.
Sources & references
8 sources cited across this report